VESALIUS-CV trial: Can lowering cholesterol prevent a first heart attack or stroke?

One of the most important questions in preventive cardiology is whether we can prevent serious heart problems before they happen.

The VESALIUS-CV trial, published in the New England Journal of Medicine, offers encouraging evidence.

🔬 What did researchers find?

The study included 12,257 people at high risk of cardiovascular disease who had not previously experienced a heart attack or stroke.

Participants received either evolocumab, a medication that significantly lowers LDL cholesterol, or a placebo, alongside their usual cholesterol-lowering treatment.

📊 The results were impressive:

✅ 25% lower risk of heart attack, stroke, or death from coronary heart disease.

✅ 19% lower risk when procedures to restore blood flow to the heart or other arteries were also included.

Over five years, the estimated risk of the first group of events was 6.2% with evolocumab, compared with 8.0% with placebo.

💡 Why does this matter?

We often think about cholesterol treatment after someone has already had a heart attack or stroke.

But this study suggests that, for people at high risk, lowering cholesterol more intensively may help prevent these events from happening in the first place.

The big takeaway: We shouldn't wait for the first heart attack or stroke to take cardiovascular prevention seriously.

Identifying people at high risk and treating elevated cholesterol effectively could make a meaningful difference.

📚 Study: Bohula EA et al. New England Journal of Medicine. 2026;394:117–127.

#HeartHealth #CardiovascularPrevention #Cholesterol #PreventiveCardiology #VESALIUSCV